TMCnet - World's Largest Communications and Technology Community



Research and Markets: Global Bronchiectasis Therapeutics Pipeline Review 2014 - Analysis of 15 Companies & 19 Drug Profiles
[April 28, 2014]

Research and Markets: Global Bronchiectasis Therapeutics Pipeline Review 2014 - Analysis of 15 Companies & 19 Drug Profiles

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Bronchiectasis - Pipeline Review, H1 2014" report to their offering.

This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.


  • The report provides a snapshot of the global therapeutic landscape of Bronchiectasis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Companies Involved in Therapeutics Development

  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Gilead Sciences, Inc.
  • Grifols, S.A.
  • Chiesi Farmaceutici SpA
  • Zambon Company S.p.A.
  • Bayer AG
  • Kamada Ltd.
  • Nostrum Pharmaceuticals, LLC
  • Pulmatrix, Inc.
  • Edmond Pharma Srl
  • Savara Inc.
  • Clarassance, Inc.
  • Alitair Pharmaceuticals, Inc.
  • Serendex Pharmaceuticals A/S

Drug Profiles

  • ARD-3150
  • ciprofloxacin
  • aztreonam
  • ARD-3100
  • R&D Progress
  • AZD-5069
  • alpha-1-proteinase inhibitor (human)
  • BAY-858501
  • vancomycin
  • GSK-2793660
  • erdosteine
  • CG-1011
  • Neutrophil Elastases Inhibitors
  • PUR-0400
  • dapsone
  • ALT-07
  • sargramostim
  • PUR-1000
  • ZP-044

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy